For most of pharmacy’s history, the economics have been relatively easy to understand. A prescription is filled, the pharmacy is reimbursed, and some portion of that transaction supports the business.
AnewHealth is building around a different equation.
On November 2, healthcare-focused private equity firm Linden Capital Partners announced a strategic investment in AnewHealth alongside a significant new investment from existing investor Nautic Partners. Linden and Nautic will jointly govern the company, while existing investor The Vistria Group will retain a minority stake. Financial terms were not disclosed.
The investment itself is not the most interesting part of the story. What deserves pharmacists’ attention is the kind of pharmacy business those investors are backing.
AnewHealth specializes in patients with complex chronic medical needs and now says it provides pharmacy services to more than 160,000 people nationwide, an increase of nearly 50% over the past two years. Its customers include risk-bearing and value-based care organizations, primary and specialty care groups, managed care plans, home health organizations, and Programs of All-Inclusive Care for the Elderly, better known as PACE.
That changes the economic role pharmacy can play.
When the organization buying pharmacy services is financially responsible for more of a patient’s overall healthcare costs, the value of the pharmacist no longer has to end with the prescription. Better medication management can potentially become valuable because of what happens elsewhere in the healthcare system.
AnewHealth says its model has helped its healthcare partners achieve an average 5% reduction in total cost of care. That figure comes from the company and has not been independently established by the investment announcement itself, so it should be treated as a company-reported outcome rather than definitive proof of causation.
Even with that caveat, the business model points toward a much larger idea.
The future of pharmacy may not depend only on getting paid more for the prescription. It may increasingly depend on getting paid because medication expertise changes what happens after the prescription.
Value-based care changes who benefits when the pharmacist does a good job
Consider an older adult living with diabetes, heart failure, hypertension, kidney disease, and several other chronic conditions. They may take ten or more medications, see multiple prescribers, move between care settings, and face frequent changes to their regimen.
In a traditional pharmacy transaction, the economic focus is mostly on getting each prescription dispensed accurately and reimbursed.
Now imagine that the organization responsible for this patient is operating under a model where it has financial accountability for a much broader portion of the patient’s care.
Suddenly, an avoidable hospitalization matters financially. An emergency department visit matters. A medication-related fall matters. Poor adherence that leads to disease deterioration matters. An unnecessary drug that continues for another year matters.
CMS describes value-based care as an approach that focuses healthcare organizations on quality, provider performance, care coordination, patient experience, and overall health rather than simply paying for isolated services. In risk-bearing arrangements, organizations can also become financially accountable for whether the total cost of care rises above or falls below expected levels.
That creates a different incentive for pharmacy.
A pharmacist who prevents a medication-related problem may create value far beyond the margin attached to one prescription.
PACE makes this economic alignment especially visible
AnewHealth’s long relationship with PACE programs helps explain why this model is interesting.
PACE programs serve older adults who generally meet a nursing-home level of care but can continue living in the community with coordinated support. The model combines Medicare and Medicaid financing and requires an interdisciplinary approach to care. Importantly, CMS describes PACE as using capitated, integrated financing while the provider assumes full financial risk for the participants it serves.
That means medication decisions can affect the same organization’s broader financial performance.
If poor medication management contributes to an emergency visit or hospitalization, the consequences do not disappear into another part of the healthcare system. If better medication management helps prevent an avoidable event, the organization has a stronger economic reason to care.
AnewHealth’s CareKinesis business provides pharmacy and medication-management services to PACE organizations, while its Pharmastar operation provides PBM capabilities designed specifically for the PACE environment. The company says it supports more than 100 PACE centers through pharmacy services and works with more than 120 PACE partners through its PBM platform.
This is an important distinction for pharmacists.
The customer is not only buying pills.
The customer is buying a medication-management capability inside a larger care model.
The pharmacist becomes more valuable when medication problems become someone else’s financial problem
Think about the types of medication issues pharmacists encounter every day.
A patient may be taking duplicate therapy. Another may have stopped an important medication because the refill process became confusing. Someone else may be using an expensive drug when a clinically appropriate lower-cost option exists. A recently discharged patient may have two conflicting medication lists, while another patient experiences dizziness that could eventually lead to a fall.
In a volume-driven model, these problems are important clinically, but solving them does not always produce a clear revenue event for the pharmacy.
A value-based model changes the question.
If the organization paying for pharmacy services is also concerned about hospitalizations, emergency visits, complications, adherence, and total healthcare spending, the pharmacist’s intervention becomes connected to outcomes that have economic consequences.
That is what makes the AnewHealth model worth studying.
The pharmacist’s value is no longer defined only by what happens at the point of dispensing. It can extend downstream into what happens to the patient over the following days, weeks, and months.
AnewHealth is combining pharmacy services with medication-management technology
This is not simply a traditional pharmacy with a different contract.
AnewHealth describes itself as a pharmacy care management company that combines comprehensive pharmacy services, clinical expertise, proprietary medication-management technology, PBM services, and PACE-specific capabilities. Its broader infrastructure includes pharmacy fulfillment centers, pharmacists, technicians, and technology designed to help care teams manage patients with complex medication needs.
Its PACE technology, for example, can provide care teams with medication-fill information, allergies, delivery status, clinical insights at the point of prescribing, electronic prescribing, and communication with the pharmacy team. The platform can also notify care teams when medications are discontinued and integrate with PACE electronic health records.
That matters because complex medication management is not one intervention.
It is a system.
A pharmacist may identify an inappropriate medication, but the information still has to reach the prescriber. A medication may be clinically correct, but the patient still needs access to it. A regimen may look appropriate in the chart while the patient is taking something completely different at home.
Technology can help organize those moving pieces.
The pharmacist then provides the judgment that determines what to do with them.
The traditional pharmacy metric is volume. Value-based pharmacy needs different metrics.
Prescription count is easy to measure.
So are revenue per prescription, acquisition cost, reimbursement, inventory turns, and gross margin.
The metrics become more complicated when pharmacy is expected to influence the patient’s broader healthcare journey.
Now an organization may want to know whether medication adherence improved, whether unnecessary therapies were eliminated, whether care transitions became safer, whether emergency visits declined, or whether hospitalizations changed.
AnewHealth says its PACE pharmacy services are designed to reduce medication risk, promote adherence, and support better clinical and cost outcomes. The company also publishes client-reported outcomes and internal measures related to emergency department use, hospitalizations, medication-risk scores, and medical costs. These figures are useful signals about how the company is positioning its value, but they should be interpreted as company- or client-reported outcomes rather than independent evidence that pharmacy services alone caused each result.
That measurement challenge will matter across the profession.
If pharmacists want to be paid for improving outcomes, pharmacy has to become better at proving which outcomes actually changed.
This is why total cost of care is such a different concept from drug cost
Pharmacy has traditionally spent enormous energy debating drug prices and pharmacy reimbursement.
Those questions remain important.
Total cost of care asks something broader.
A more expensive medication could potentially reduce downstream spending if it prevents costly complications. A cheaper medication may save money immediately but create poor value if patients cannot tolerate it or do not take it. Removing an unnecessary drug might reduce both prescription spending and the risk of an adverse event.
The medication cannot be evaluated only by its acquisition cost.
Its value depends partly on what happens next.
CMS uses total cost of care approaches to hold organizations accountable for both quality and spending across a defined population or set of services. The underlying idea is that healthcare organizations should have incentives to improve outcomes while avoiding unnecessary costs rather than earning more simply because more services occur.
For pharmacists, this shifts the economic conversation from the prescription toward the patient journey.
That is a much larger playing field.
Medication complexity creates economic leverage for the PharmD
Patients with complex chronic conditions are exactly where this model becomes interesting.
The more medications someone takes, the more opportunities exist for duplication, interactions, adherence problems, prescribing cascades, access barriers, confusion, and medication-related harm.
AnewHealth says it specializes in patients taking multiple medications who often have several chronic conditions and multiple prescribers. Its pharmacy operations include more than 200 pharmacists focused on complex medication routines.
That creates a simple economic insight.
The more complicated medication use becomes, the greater the potential value of managing it well.
A pharmacist who helps optimize a five-dollar prescription may create relatively little direct savings. The same pharmacist who identifies a medication combination contributing to repeated falls could potentially influence thousands of dollars in downstream healthcare use.
The value is no longer attached only to the price of the product.
It is attached to the decision surrounding the product.
Care moving toward the home makes medication management even more important
Linden highlighted another trend when announcing its investment.
The firm specifically pointed to AnewHealth’s position at the intersection of pharmacy services, technology, and value-based care while noting the movement of medically complex patients toward lower-cost home and community settings.
Those trends reinforce one another.
Patients who once might have spent more time in institutional settings are increasingly receiving care at home or in community-based programs. At the same time, their medication regimens may remain highly complex.
That creates an operational challenge.
Inside a hospital, healthcare professionals can see medication administration records, laboratory results, vital signs, and other clinical information within one environment. At home, medication management becomes much more distributed.
The patient may see several prescribers. Family caregivers may become responsible for day-to-day administration. Prescriptions can change after hospitalizations or specialist visits. Adherence becomes harder to observe.
The medication continues affecting the patient every day, even when a healthcare professional is not physically present.
Pharmacy is naturally positioned inside that gap.
The pharmacist can become part of the infrastructure that keeps complex patients at home
This may be one of the most important future opportunities for the profession.
As more care moves into the home, healthcare systems need infrastructure that can follow the patient between physician visits.
Medication management is one obvious piece.
A pharmacist can help maintain an accurate regimen, identify changes, monitor adherence, address access problems, simplify schedules, review potential adverse effects, and communicate relevant information back to the care team.
That work can support the larger goal of keeping medically complex patients stable outside expensive acute-care settings.
It does not mean pharmacists alone prevent hospitalizations. Outcomes for complex patients depend on physicians, nurses, caregivers, social factors, disease severity, and many other variables.
The opportunity is that medication management becomes one of the controllable pieces inside a much larger system.
When organizations become financially accountable for that system, pharmacy becomes easier to value.
Investors are paying attention to that intersection
Private equity investment is not proof that a healthcare model works clinically.
Investors make decisions for many reasons, and their objective is ultimately financial return.
Still, investment decisions can reveal where sophisticated buyers believe future healthcare demand may grow.
Linden describes AnewHealth as operating at the intersection of pharmacy services, technology, and value-based care. Nautic, which first invested through ExactCare Pharmacy in 2016, is reinvesting as the company expands its clinical services, infrastructure, and patient reach.
Independent transaction coverage likewise describes AnewHealth as a pharmacy company focused on people with complex medical needs who are served by risk-bearing and value-based organizations.
That combination is worth paying attention to.
The investors are not simply backing another chain of prescription counters.
They are backing a company whose business case is built around managing complex medication use inside organizations that care about broader healthcare outcomes.
Value-based care may finally align pharmacy economics with pharmacy’s strongest argument
For years, pharmacists have argued that their value extends far beyond dispensing.
The profession has a strong clinical case for that argument.
The economic case has often been harder.
A pharmacist may prevent a medication problem, but the financial benefit could appear somewhere else. The hospital avoids an admission. The payer avoids a claim. The employer avoids a healthcare expense. The patient avoids a complication.
Meanwhile, the pharmacy may receive no additional payment for creating that value.
Risk-bearing models create the possibility of better alignment because the organization buying the pharmacy service may also benefit when downstream costs fall.
That does not automatically mean the pharmacist gets paid appropriately.
Contracts still matter. Measurement matters. Attribution matters. Organizations need evidence that the pharmacy intervention contributed enough value to justify its cost.
However, the incentive structure begins to make more sense.
The same organization that pays for medication management may also have a financial interest in better medication outcomes.
This changes what pharmacists should learn about business
Pharmacists interested in the future of the profession should become more comfortable with the economics behind these models.
Terms such as total cost of care, capitation, downside risk, risk adjustment, value-based contracting, quality measures, and return on investment are increasingly relevant to medication management.
They explain why one organization may happily invest in a pharmacist service while another refuses to pay for the exact same intervention.
The clinical work can be identical.
The financial incentives surrounding it may be completely different.
That distinction is important for pharmacy entrepreneurs too.
Before asking whether a patient or organization would benefit from a service, ask who financially benefits when the service works.
If a pharmacist-led program reduces avoidable hospitalization, who saves the money?
If better adherence improves a quality measure, who gets rewarded?
If medication simplification reduces adverse events, which organization bears those costs today?
Those questions help reveal where the customer may actually be.
The strongest pharmacy business models may follow the money downstream
This is also why pharmacy entrepreneurs should look beyond the prescription itself.
Imagine building a service that improves medication adherence by 10%.
That sounds useful.
But the business question is what that improvement changes.
If better adherence helps a health plan improve quality metrics, the health plan may care. If it helps a risk-bearing physician group avoid complications, that group may care. If it reduces hospitalizations among PACE participants, the PACE organization may have a financial reason to support it.
The economic value emerges downstream.
AnewHealth’s model is interesting because it works with organizations whose incentives already extend downstream.
The pharmacy company can therefore position medication management as part of a larger strategy for managing complex patients rather than as an isolated prescription service.
That may be where many of the strongest future pharmacy business models develop.
The 5% claim should make pharmacists curious, not unquestioning
AnewHealth’s statement that its model produces an average 5% reduction in total cost of care is a striking number. For a large risk-bearing organization, even a small percentage reduction in overall healthcare spending can represent meaningful dollars.
However, the public investment announcement does not provide enough methodological detail to independently determine how that 5% was calculated, which populations were included, what comparison was used, or how much of the reduction can be attributed specifically to AnewHealth’s pharmacy model.
That is important.
Healthcare companies increasingly market themselves around outcomes. Pharmacists should be sophisticated consumers of those claims.
Ask who measured the outcome, what the baseline was, which patients were included, how long they were followed, whether there was a comparison group, and whether the results have been independently evaluated.
The business signal can still be meaningful while the evidence remains incomplete.
Investors clearly see enough opportunity to commit new capital.
That does not mean pharmacists should stop asking for data.
The bigger signal is what pharmacy is being asked to accomplish
The most interesting part of the AnewHealth story is not the exact percentage.
It is the outcome being discussed at all.
The company is not positioning its value around how many prescriptions it can fill per hour.
It is talking about patient outcomes, medication risk, healthcare utilization, and total cost of care.
That is a fundamentally different way to describe what a pharmacy company does.
It also points toward a different way to describe pharmacist value.
Instead of asking how efficiently the pharmacist moved the product, the organization can ask whether the medication strategy improved.
Was unnecessary therapy removed? Did the patient remain adherent? Were medication risks identified? Did the care team have better information? Did the patient stay out of the emergency department?
Those questions move pharmacy closer to the outcomes healthcare organizations increasingly care about.
Follow one intervention all the way downstream
There is a simple exercise pharmacists can use to start thinking this way.
Think about one medication intervention you made recently. Maybe you identified duplicate therapy, corrected an inappropriate dose, solved an access problem, improved adherence, changed an expensive treatment, or caught a meaningful interaction.
Now follow that intervention beyond the prescription.
What might have happened if nobody intervened?
Perhaps nothing serious would have occurred. That is possible and important to acknowledge.
But maybe the patient would have stopped treatment. Perhaps the adverse effect would have worsened. An interaction could have created another medical visit. Poor control of a chronic condition might eventually have led to urgent care or hospitalization.
Then ask who would have paid for that downstream event.
The patient? Medicare? A health plan? An employer? A risk-bearing medical group?
Finally, ask whether the pharmacist who reduced that risk captured any of the economic value created.
That is the question value-based pharmacy is trying to solve.
The future of pharmacy may be measured by what happens after the prescription
AnewHealth’s new investment does not prove that value-based pharmacy has solved the profession’s reimbursement challenges.
It does show that serious healthcare investors see potential in a pharmacy company built around complex patients, medication-management technology, clinical pharmacy services, and organizations that bear financial responsibility for broader healthcare outcomes.
The timing matters.
Care is moving toward the home and community. Payment models increasingly emphasize outcomes and total cost. At the same time, medication regimens are becoming more complicated, specialty therapies are becoming more expensive, and medically complex patients need more coordination.
Those trends create a natural place for pharmacist expertise.
The question is whether pharmacy can prove its value clearly enough to become part of the economic infrastructure surrounding those patients.
For decades, the prescription itself has been the center of the pharmacy business model.
Value-based care offers another possibility.
The future of pharmacy may not be about getting paid more for the prescription.
It may be about getting paid because the pharmacist changes what happens after it.
Resources & Citations
- AnewHealth and Linden Capital Partners. “AnewHealth Announces Strategic Growth Investments from Linden Capital Partners and Nautic Partners.” November 2, 2026. The companies announced a strategic investment from Linden and a new investment from existing investor Nautic. Financial terms were not disclosed. AnewHealth reports serving more than 160,000 pharmacy patients, representing nearly 50% growth over two years, and reports an average 5% reduction in total cost of care among organizations it serves.
- Private Equity Professional. “Linden Capital Partners and Nautic Partners Invest in AnewHealth.” November 3, 2026. Independent transaction coverage describes AnewHealth’s focus on pharmacy care for complex patients served by risk-bearing and value-based healthcare organizations, including PACE programs.
- Linden Capital Partners. “AnewHealth.” Current portfolio overview. Linden describes AnewHealth as a pharmacy care management company combining clinical pharmacy services, proprietary medication-management technology, PBM services, and PACE solutions for risk-bearing providers, health plans, and other care organizations.
- AnewHealth. “PACE Pharmacy Services from CareKinesis.” Current company overview. AnewHealth describes its medication-management model, PACE technology, clinical pharmacy services, medication-risk management, and company- and client-reported outcomes related to healthcare utilization and costs.
- AnewHealth. “PACE Organizations.” Current company overview. The company describes its PACE pharmacy, PBM, risk-adjustment, and consulting capabilities and reports serving more than 100 PACE centers through pharmacy services.
- Centers for Medicare & Medicaid Services. “Value-Based Care.” CMS describes value-based care as a model focused on quality, care coordination, provider performance, patient experience, and overall health rather than payment based solely on individual services.
- Centers for Medicare & Medicaid Services. PACE waiver guidance. CMS identifies comprehensive integrated care, interdisciplinary care delivery, capitated financing, and assumption of full financial risk as core features of the PACE model.
- Centers for Medicare & Medicaid Services. “Total Cost of Care and Hospital Global Budgets” and value-based payment guidance. CMS describes total-cost-of-care approaches and payment models in which healthcare organizations may assume financial accountability for quality and overall spending across defined populations.